Medical Marketing & Media

Better treatments buoy multiple-myeloma patients, bound by research cuts and racial disparities

Multiple myeloma is a cancer that develops in bone marrow plasma cells, crowding out healthy blood cells and damaging the bones.
The American Journal of Managed Care

Defining the Comprehensive Role of the Oncology Pharmacist in Multiple Myeloma: Marcus Flores, PharmD, BCPS, BCOP

Marcus Flores, PharmD, BCPS, BCOP, discusses the vital role of pharmacists in multidisciplinary cancer care, exploring ...
Frontiers

Patients with anti-SAE+ dermatomyositis display refractory and difficult-to-treat skin manifestations: case series from two Italian cohorts and review of literature

Aim: We aimed to describe the clinical and serological characteristics of anti-small ubiquitin-like modifier-activating enzyme (SAE)-positive cases from a multicentric cohort of patients affected with ...
Targeted Oncology

Iberdomide Triplet Regimen Signals Deep Responses in Multiple Myeloma

The iberdomide, daratumumab, and dexamethasone regimen achieved a 93.1% overall response rate in transplant-ineligible multiple myeloma patients. Frailty significantly impacted survival outcomes, with ...